| Catalog No. | HV121016 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Humanized |
|---|
| Isotype | IgG2-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | IL-31RA, Interleukin-31 receptor subunit alpha, IL31RA, hGLM-R, ZcytoR17, IL-31R-alpha, GPL, CRL3, Cytokine receptor-like 3, IL-31R subunit alpha, IL-31 receptor subunit alpha, Gp130-like receptor, GLM-R, Gp130-like monocyte receptor |
|---|
| Concentration | 2.5mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | Q8NI17 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -280°C. |
|---|
| Alternate Names | CIM331,CAS:1476039-58-3,Nemolizumab |
|---|
| Background | Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD). |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
